These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial. Weller J; Zeyen T; Schäfer N; Schaub C; Potthoff AL; Steinbach JP; Hau P; Seidel C; Goldbrunner R; Tabatabai G; Vatter H; Tzaridis T; Schneider M; Herrlinger U J Neurooncol; 2023 Sep; 164(3):749-755. PubMed ID: 37787906 [TBL] [Abstract][Full Text] [Related]
8. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Bian B; Li L; Yang J; Liu Y; Xie G; Zheng Y; Zeng L; Zeng J; Shen L Cancer Cell Int; 2019; 19():259. PubMed ID: 31624472 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis. Qin G; Li X; Chen Z; Liao G; Su Y; Chen Y; Zhang W Mol Neurobiol; 2017 Jul; 54(5):3264-3270. PubMed ID: 27090900 [TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Kovic B; Xie F J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504 [TBL] [Abstract][Full Text] [Related]
14. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599 [TBL] [Abstract][Full Text] [Related]
15. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142 [TBL] [Abstract][Full Text] [Related]
17. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269 [TBL] [Abstract][Full Text] [Related]
18. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. Holst CB; Christensen IJ; Skjøth-Rasmussen J; Hamerlik P; Poulsen HS; Johansen JS Front Oncol; 2020; 10():478. PubMed ID: 32363159 [No Abstract] [Full Text] [Related]
19. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816 [TBL] [Abstract][Full Text] [Related]
20. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Brandes AA; Mason W; Pichler J; Nowak AK; Gil M; Saran F; Revil C; Lutiger B; Carpentier AF Future Oncol; 2014 May; 10(7):1137-45. PubMed ID: 24947255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]